| Theme | Molecular Medicine of Gastrointestinal Disorders : from Basics to Applications | |
|---|---|---|
| Title | Aberrant DNA Methylation Involved in Digestive Diseases | |
| Publish Date | 2009/02 | |
| Author | Takao Maekita | Second Department of Internal Medicine, Wakayama Medical University |
| Author | Shotaro Enomoto | Second Department of Internal Medicine, Wakayama Medical University |
| Author | Kimihiko Yanaoka | Second Department of Internal Medicine, Wakayama Medical University |
| Author | Kazuyuki Nakazawa | Second Department of Internal Medicine, Wakayama Medical University |
| Author | Masashi Oka | Second Department of Internal Medicine, Wakayama Medical University |
| Author | Masao Ichinose | Second Department of Internal Medicine, Wakayama Medical University |
| [ Summary ] | Recent studies have revealed that epigenetic alterations, such as aberrant DNA methylation, are deeply involved in various digestive diseases. It is widely accepted that CGI methylation in the gene promoter region plays a pivotal role in the control of gene transcription. As for cancer derived from digestive organs, aberrant DNA methylation and the resulting derangement in transcriptional control of various "tumor suppressor genes" are frequently observed. Recently, a considerable number of approaches have been employed to search for methods to use unique DNA methylation patterns in various gene regions as stratification markers to predict an individual's genetic or acquired susceptibility to cancer. Recently, the US Food and Drug Administration (FDA) approved treatment with demethylating agents (5-aza-cytidine and 5-aza-2'-deoxycytidine) for myelodysplastic syndrome (MDS). Epigenetic therapies, such as Azacytidine, will probably usher in a new era in the management of digestive diseases. We are beginning to understand how to control epigenetic derangement involved in cancer development and optimally use this group of agents in order to achieve maximum benefits. |
|